症状性下肢动脉疾病抗栓治疗分析

目的 探讨小剂量利伐沙班联合抗血小板药对症状性下肢动脉疾病患者的治疗效果。结论 回顾性分析167例下肢动脉粥样硬化病变患者,分为观察组和对照组,观察组为利伐沙班(2.5 mg, 2次/d)联合抗血小板药物西洛他唑(100 mg, 2次/d),对照组单联抗血小板西洛他唑(100 mg, 2次/d)。2组治疗并随访18个月,观察主要肢体不良事件、主要心脑血管事件以及主要出血事件。结果 观察组主要心脑血管事件、肢体主要不良事件较对照组明显下降(P<0.05),主要出血事件在两组比较差异无统计学意义(P>0.05)。方法 小剂量利伐沙班联合抗血小板药物西洛他唑可明显减少症状性下肢动脉疾病的心脑血管和肢体主要不良事件,改善预后,且具有安全性。

Analysis of antithrombotic therapy for symptomatic lower extremity atherosclerosis disease

Objective To explore the curative effects of low-dose rivaroxaban combined with ant-platelet drugs for symptomatic lower extremity atherosclerosis disease(LEASD).Methods The data of 167 LEASD patients were retrospectively analyzed and divided into observation group and control group. Patients in observation group were treated with antithrombotic therapy using rivaroxaban (2.5 mg, bid) combined with anti-platelet drug namely cilostazol (100 mg, bid), and those in control group with the same dose of cilostazol alone (100 mg, bid). A 18-month follow-up was performed. The key observation was major adverse limb events(MALEs), major adverse cardiovascular events(MACEs) and adverse bleeding events(MBEs).Results MACEs and MALEs were significantly lower in observation group than in control group (P<0.05). No differences were statistically significant in MBEs between groups (P>0.05).Conclusion For LEASD patient, low-dose rivaroxaban combined with anti-platelet drug namely cilostazol can significantly reduce MACEs and MALEs, and improve prognosis with safety.